- Standard BioTools (LAB, Financial) launches its inaugural Proteomics Roundtable Series.
- The first session, focused on proteomics in cancer research, is set for June 6, 2025.
- Renowned experts from Imperial College London and the University of Oxford will participate.
Standard BioTools Inc. (LAB) has announced the launch of its inaugural Proteomics Roundtable Series, a virtual event aimed at fostering discussions on the advancements and real-world applications of proteomics in healthcare. The series will highlight key developments and technological innovations that are shaping the future of this scientific field.
The first session, titled "Is More Really More? Evaluating the Case for High-Plex, High-Quality Proteomics," is scheduled for June 6, 2025, at 11:00 am ET. Dr. Stephen Williams, Chief Medical Officer at Standard BioTools, will host the panel. The session will feature insights from the 30-year EPIC cancer study involving 500,000 participants, with contributions from esteemed experts Dr. Elio Riboli and Dr. Marc Gunter, both from Imperial College London, and Dr. Karl Smith-Byrne from the University of Oxford.
Future sessions in the series will address crucial topics in proteomics research, including comparative metrics for proteomic platforms, deployment of these technologies in biobanks, and their application in drug development clinical trials. Registration for these events is available on the Standard BioTools website, and the sessions will be webcast on the company's Investor page for future replay.
Standard BioTools, a leader in providing standardized next-generation technologies, continues to support pioneering research in translational and clinical studies, driving improved patient outcomes through its innovative solutions.
